Loading company…
NovoCodex develops biological drugs, including therapies targeting HER2-positive cancers.
NovoCodex develops biological drugs for cancer, including the HER2-targeted drug ARX788, which was in clinical research for breast and gastric cancer. Founded in Shaoxing, China, in 2017, the company raised Series C funding in March 2026 from Dongguan Financial Holdings Group, CITIC Med Fund, Puhua Capital, Zhejiang Xinhai Asset Management, Minnesota Capital and Prosperity Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in